ESMO 2023 | TIDE-A: avelumab and intermittent axitinib in metastatic renal cell carcinoma

Roberto Iacovelli, MD, Agostino Gemelli University Policlinic, Rome, Italy, gives an overview of the Phase II TIDE-A trial (NCT04698213), which assessed avelumab with intermittent axitinib, a tyrosine kinase inhibitor, in patients with treatment-naïve metastatic renal cell carcinoma (mRCC). The primary endpoint, the rate of patients free of progression eight weeks after axitinib discontinuation, was met, enabling patients to safely receive treatment with reduced toxicity. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.